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ABSTRACT
Introduction: Over the last year, multiple,
potentially practice-changing, cardiology trials
or studies have been published or presented at
international meetings including the American
College of Cardiology, European Association for
Percutaneous Cardiovascular Interventions,
European Society of Cardiology, Transcatheter
Cardiovascular Therapeutics, Heart Failure
Congress, Heart Rhythm Society, Heart Failure
Society of America, American Society of
Hypertension and the American Heart
Association.
Methods: Clinical trial results presented at
major cardiology conferences during 2014
were reviewed by the authors. Search terms
included heart failure (HF), acute coronary
syndrome, stable coronary disease,
interventional cardiology, atrial fibrillation,
electrophysiology and coronary prevention.
Selection criteria were trials of broad relevance
to the cardiology community, those with
potential to change current practice and those
with potential to guide further phase III
research.
Results: In this paper, the authors describe and
place in clinical context, new HF, data
including neprilysin inhibitors, intravenous
ferric carboxymaltose, potassium-absorbing
compounds, quadripolar leads for cardiac
resynchronization therapy and intraventricular
device intervention. New trial data are also
described for acute coronary syndromes
(clopidogrel, prasugrel, ticagrelor), stable
coronary artery disease (ivabradine),
percutaneous coronary intervention (the role
of thrombectomy or treatment of non-culprit
lesions during primary intervention, pressure
wire studies and outcomes of new stent
designs), transcatheter aortic valve
intervention data, atrial fibrillation
(anticoagulation and direct current
cardioversion), electrophysiology (leadless
pacemaker devices, use of quinidine in
Brugada syndrome) and coronary prevention
(landmark Ezetimibe outcome data, PCSK9
clinical trials, childhood prevalence of
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hypertension, renal denervation for resistant
hypertension and the role of cardiac
computerized tomography in cardiovascular
screening).
Conclusion: This paper summarizes key clinical
trials during 2014 and should be of practical
interest to clinicians and cardiology researchers.
Keywords: Acute coronary syndromes;
Anticoagulation; Antiplatelet; Atrial
fibrillation; Bioabsorbable polymer;
Cardiology; Heart failure; Myocardial
infarction; Pacemaker; Revascularization
INTRODUCTION
Cardiovascular (CV) medicine is a specialty
defined by research milestones [1]. This strong
research ethos and abundance of emerging
research can make it difficult for the clinical
cardiologist to keep up to date with the latest
evidence. Throughout 2014, a number of
breaking trials have been presented at major
international cardiology conferences with the
potential to impact guidelines and practice. In
this paper, we describe and place in clinical
context new data for heart failure (HF), acute
coronary syndrome, stable coronary disease,
interventional cardiology, atrial fibrillation,
electrophysiology and coronary prevention.
METHODS
Clinical trial results presented at major
cardiology conferences during 2014 were
reviewed by the authors. Conferences included
the American College of Cardiology (ACC),
European Association for Percutaneous
Cardiovascular Interventions (EuroPCR),
European Society of Cardiology (ESC),
Transcatheter Cardiovascular Therapeutics
(TCT), Heart Failure Congress, Heart Rhythm
Society (HRS), Heart Failure Society of America
(HFSA), American Society of Hypertension
(ASH), Society for Cardiovascular Angiography
Interventions (SCAI) and the American Heart
Association (AHA). Search terms included heart
failure, acute coronary syndrome, stable
coronary disease, interventional cardiology,
atrial fibrillation, electrophysiology and
coronary prevention. Selection criteria were
trials of broad relevance to the cardiology
community, those with potential to change
current practice and those with potential to
guide further phase III research. This article is
based on previously conducted studies and does
not involve any new studies of human or




For the past two decades, angiotensin-
converting enzyme (ACE) inhibitors have been
considered the cornerstone of HF therapy.
Neprilysin is a neutral endopeptidase which
degrades potentially beneficial natriuretic and
vasoactive peptides. The prospective
comparison of ARNI with ACEI to Determine
Impact on Global Mortality and Morbidity in
HF (PARADIGM-HF) study (ClinicalTrials.gov
#NCT01035255) randomized 8442 patients
with reduced left ventricular (LV) ejection
fraction and New York Heart Association
(NYHA) class II–III symptoms to LCZ696 (a
combination of the neprilysin inhibitor
sacubitril and valsartan) or to standard
treatment with enalapril [2]. The trial was
stopped early after a mean follow-up of
27 months, at which point LCZ696 compared
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with enalapril resulted in a 20% decrease in
primary end point of CV death or HF
hospitalization [hazard ratio (HR) in the
LCZ696 group, 0.80; 95% confidence interval
(CI), 0.73–0.87; p\0.001) (Fig. 1) [2], a 20%
reduction in CV death (HR 0.80; 95% CI
0.71–0.89; p\0.001) and a 16% reduction in
the pre-specified key single end point of all-
cause mortality [HR 0.84 (95% CI 0.76–0.93);
p\0.001]. LCZ696 also reduced the risk of
HF hospitalization by 21% (p\0.001) and
decreased the symptoms and physical
limitations of HF (p = 0.001). It is worth
noting that the dose of enalapril used may
have been suboptimal (maximum 10 mg twice
daily vs. the maximum valsartan dose of 320 mg
daily). The incidence of numerically greater, but
non-significant excess of angioedema with
LCZ696 may have been underestimated by use
of a careful run-in period to exclude intolerant
patients. Nevertheless, assuming LCZ696
receives a license, it is likely to be quickly
included in clinical HF guidelines given its
highly significant reduction in CV mortality
and all-cause mortality.
The role of iron supplementation for patients
with HF and anemia has been controversial.
The Ferric CarboxymaltOse evaluatioN on
perFormance in patients with IRon deficiency
in coMbination with chronic Heart Failure
(CONFIRM HF) study (ClinicalTrials.gov
#NCT01453608) provided an important
addition to the literature [3]. In this study, 304
HFpatients (definedasLVejection fraction\45%,
NYHA II-III), with increased brain natriuretic
peptide and serum ferritin \100 ng/mL
(or 100–300 ng/mL if transferrin saturation
was \20%) were randomized to intravenous
Fig. 1 The primary end point of cardiovascular death or HF hospitalization taken with permission from PARADIGM-HF.
Reproduced with permission from [2]. HR hazard ratio
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ferric carboxymaltose or placebo given at time
points of baseline, 6, 12, 24, and 36 weeks. The
trial’s primary end point, the 6-minute walk test
duration at 24 weeks, was significantly improved
in the intravenous iron group (33 m greater
distance; p = 0.002), as were the secondary
outcomes of NYHA class, fatigue score, quality of
life scores, and self-reported patient global health
assessment (p\0.05 for all). Treatment with
intravenous iron was also associated with a
significant reduction in the risk of HF
hospitalizations [HR 0.39 (95% CI 0.19–0.82);
p = 0.009]. The study was not powered to detect
difference in mortality. In keeping with previous
studies, CONFIRMHF supports iron treatment in
HF patients with low ferritin.
A recurrent concern of HF patients is the
presence of hyperkalemia. Reasons for this
include concomitant renal failure and the use
of drugs such as renin–angiotensin–aldosterone
inhibiting agents and aldosterone antagonists.
A potassium-absorbing compound, patiromer,
was used in a two-phase trial, with
hyperkalemic patients randomized to either
placebo or this new drug with the dose
depending on their initial serum potassium
[4]. In the initial single-blind phase of the
study, 102 patients with HF and 141 without
received patiromer at two different dosage
levels. Compared with placebo, there was a
sustained decrease in serum potassium, both in
patients with (p\0.001) and without
(p\0.001) HF. The second phase of the study
looked at patients who had received patiromer
and who were taking a renin–angiotensin–
aldosterone inhibiting agent. In this phase,
107 patients whose initial potassium was[5.5
to \6.5 mEq/L and subsequently decreased to
3.8 to\5.5 mEq/L were randomized to continue
patiromer (n = 55) or to switch to placebo
(n = 52) and were followed for another
8 weeks. Switching patiromer to placebo led to
a significant increase in potassium compared
with maintenance, both in patients with
(n = 49) and without (n = 58) HF, with
potassium levels C5.5 mmol/l occurring in
60% of the patients in the placebo group as
compared to only 15% in the patiromer group
(p\0.001). Given these encouraging findings,
further study with patiromer is planned
including evaluation of the impact on overall
clinical outcomes.
After an anterior wall myocardial infarction
(MI), loss of myocardium results in an abrupt
increase in loading conditions that induces
remodeling of the LV [5]. Remodeling can lead
to an increased LVvolume,myocardial stress, and
subsequent HF. To date,management options are
limited for such patients. At the ESCHeart Failure
Congress 2014 results of a pooled analysis of the
first 111 patients treated with the Parachute
device were presented [6]. The Parachute device
is a percutaneous intervention that fits like an
upside-down umbrella within the left ventricle
apex aimed at improving ventricular function
(Fig. 2) [7]. All patients presented had post-MI HF
with anteroapicalwallmotion abnormalities. The
results showed that the implantation of the
device was successful in 95.5%, and at 1 year
there were a number of significant clinical
and echocardiographic improvements. These
included reductions in systolic and diastolic
volumes, a moderate but significant rise in LV
ejection fraction, and an improvement in
6-minute walk test distance and NYHA
symptoms. Given these encouraging results,
formal clinical outcome trials are now being
planned.
Percutaneous Coronary Intervention
The optimum management of non-culprit
lesions following primary percutaneous
coronary intervention (PCI) in ST-elevation MI
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(STEMI) patients continues to be a focus of
investigation. The previous Preventive
Angioplasty in Acute Myocardial Infarction
(PRAMI) trial (Current Controlled Trials
#ISRCTN73028481) [8]. reported that a
strategy of non-culprit PCI during the same
sitting as primary PCI, compared with no
further intervention, reduced the composite
end point of cardiac death, nonfatal MI, or
refractory angina. However, concerns regarding
PRAMI included possible overestimation of
treatment effect due to early stopping of a
small unblinded study. The Complete Versus
Lesion-Only Primary PCI Trial (CVLPRIT) [9],
which randomized patients to revascularization
of all stenoses [70% during index admission
not necessarily at time of primary PCI (n = 150)
vs. culprit-only PCI (n = 146), also
demonstrated significant reduction in the
primary composite end point of total
mortality, MI, HF, or ischemia-driven
revascularization at 12 months (10% vs.
21.2%; p = 0.009). Further analysis of PRAMI
was presented at the SCAI 2014 meeting and
Fig. 2 The Parachute left ventricular device. Reproduced with permission from [7]
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reported that the severity of stenosis in non-
culprit arteries was associated with future risk of
subsequent clinical events [10]. Patients with an
operator-determined 95–99% stenosis had a
47% incidence of major adverse cardiac events
(MACE), whereas patients with 75–94% stenosis
and 50–74% stenosis had a 23% and 14%
incidence of MACE, respectively. Although
CVLPRIT was relatively small and there were
no significant differences in mortality or HF
(MACE difference being driven by soft end
point of revascularization), along with PRAMI,
it supports an interventional rather than
conservative approach to non-culprit lesions.
This is in contrast to a meta-analysis of 34,279
patients published earlier in 2014, which
suggested that there was no significant
difference in hospital mortality with
multivessel PCI vs. culprit-only PCI [11].
Further prospective data are still required,
which may be provided by the Complete vs.
Culprit-only Revascularization to Treat Multi-
vessel Disease After Primary PCI for STEMI
(COMPLETE) study (ClinicalTrials.gov
#NCT01740479) which is a large ongoing trial
comparing staged non-culprit PCI with
conservative treatment [12].
The Thrombus Aspiration in ST-Elevation
Myocardial Infarction in Scandinavia (TASTE)
trial (ClinicalTrials.gov #NCT01093404)
presented its primary outcome (30 day
mortality rates) at the 2013 ESC conference
[13], and full 1-year results were presented at
ESC 2014 [14]. This large, randomized, registry
trial allocated 7244 patients to manual
thrombus aspiration followed by PCI versus
PCI only. There was no significant difference
between the two groups in all-cause mortality at
1 year (5.3% vs. 5.6%; HR 0.94; 95% CI,
0.78–1.15; p = 0.57), rehospitalization for MI
at 1 year (2.7% vs. 2.7%; HR 0.97; 95% CI
0.73–1.28; p = 0.81), stent thrombosis at 1 year
(0.7% vs. 0.9%; HR 0.84; 95% CI 0.50–1.40;
p = 0.51), or the composite of death/MI/stent
thrombosis, (8.0% vs. 8.55%; HR 0.94; 95% CI
0.80–1.11; p = 0.48). In contrast to previous
data from the smaller TAPAS trial (Current
Controlled Trials #ISRCTN16716833) [15],
TASTE did not support a role for routine
thrombus aspiration before primary PCI.
The BIOSCIENCE trial (ClinicalTrials.gov
#NCT01443104) randomized 2119 patients
undergoing PCI for chronic stable coronary
artery disease or acute coronary syndromes to
the ultrathin-strut (60 lm) cobalt–chromium
Orsiro stent (Biotronik, Berlin, Germany)
releasing sirolimus from a biodegradable poly
L-lactide polymer or to the thin-strut durable
polymer everolimus-eluting stent Xience Prime
(Abbott, Illinois, USA) [16]. The Orsiro stent met
the definition of non-inferiority vs. Xience
Prime for the primary composite end point of
cardiac death/target vessel MI/clinically
indicated target lesion revascularization at
12 months. (6.5% vs. 6.6%; p for non-
inferiority\0.0004). There was no difference in
rates of definite stent thrombosis (0.9% vs. 0.4%;
p = 0.16), although longer-term follow-up
beyond discontinuation of dual antiplatelet
therapy is of more interest when evaluating
possible benefits of a biodegradable polymer. Of
note, in a pre-specified subgroup of patients
with STEMI, the Orsiro stent was associated with
a lower incidence of the primary end point [7
(3.3%) vs. 17 (8.7%), RR 0.38, 95% CI 0.16–0.91;
p = 0.024; p for interaction = 0.014]. This
finding is consistent with previous
biodegradable vs. durable polymer stents such
as the Limus Eluted From A Durable Versus
ERodable Stent Coating (LEADERS) trial
(ClinicalTrials.gov #NCT00389220) and
warrants further study [17].
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Hypertension
The role of renal denervation for resistant
hypertension remains unclear. Several small
open-label studies with different devices had
reported treatment benefit for renal
denervation, but the Renal Denervation in
Patients With Uncontrolled Hypertension
(SYMPLICITY HTN-3) trial (ClinicalTrials.gov
#NCT01418261) [18] which randomized 535
patients (2:1) to the first-generation Symplicity
catheter (Medtronic, Santa Rosa, California,
USA) versus a sham procedure failed to show a
significant between-group difference in
6-month office blood pressure (BP) (14.1 vs.
11.7 mmHg reduction; between-group
difference 2.39 mmHg; 95% CI -6.89 to 2.12;
p = 0.26; superiority margin 5 mmHg) or 24 h
ambulatory BP (between group difference
-1.96 mmHg; 95% CI -4.97 to 1.06; p = 0.98,
superiority margin 2 mmHg). A couple of
reasons have been proposed for this lower
than expected efficacy: firstly, heterogeneity in
different patient subgroups; secondly possible
suboptimal denervation due to device/operator
factors as evident by lower BP reduction than
previous studies and only 60% of patients in
this study had only one or no ablation notches
(arterial wall edema marks post-ablation)
suggesting inadequate surface contact.
Patient selection also appears important.
Six-month data from ongoing Global
SYMPLICITY registry (ClinicalTrials.gov
#NCT01534299) of [5000 patients from [200
centers reported a 21.4 mmHg reduction in
patients with baseline systolic BP C160 mm Hg,
but only a 4.6 mmHg reduction in those with
baseline systolic BP 140–159 mmHg [19].
Greater numbers of effective ablation points
correlated with benefit. Including treatment of
accessory renal arteries also predicted better
outcome. Further randomized studies with
newer devices and studies to identify
biomarkers predictive of procedural success
are ongoing.
The Prevention Education Program (PEP)
Family Heart Study was an important study
in over 22,000 adolescents and children aged
3–18 years old [20]. Levels of BP were
recorded and compared to the markers of
obesity such as body mass index, waist
circumference, waist-to-height ratio,
percentage of body fat, and skinfold
thickness. Pre-hypertension was defined as
a BP between the 90th and 95th percentile of
the BP curve for children and adolescents,
while hypertension was a BP reading over
the 95th percentile. The prevalence of
hypertension was 5.4% in normal weight,
9.8% in overweight and 21.5% in obese
subjects. Unsurprisingly, the presence of
obesity strongly correlated with
hypertension—obese boys having an odds
ratio (OR) of 5.9 and obese girls 4.3.
Compared with normal weight subjects, the
risk of having pre-hypertension was
significantly raised in overweight males and
females (OR 1.6 and OR 1.8, respectively)
and obese males and females (OR 2.4 and OR
3.3, respectively). This study highlights the
dangers of childhood obesity.
Antiplatelet Therapy
The optimum duration of dual antiplatelet
therapy (DAPT) following coronary stenting or
acute coronary syndrome has been assessed in
several large studies during 2014. The DAPT
study (ClinicalTrials.gov #NCT00977938)
presented at AHA 2014 randomized 9961
patients who had received a drug-eluting stent
(DES) and 12 months of DAPT to aspirin only
for a further 18 months (30 in total) of DAPT
[21]. Those assigned to 30 months of DAPT
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showed significant reductions in co-primary
end points of stent thrombosis [0.4% vs. 1.4%;
HR 0.29 (95% CI 0.17–0.48); p\0.001] and the
composite of death/MI/stroke [4.3% vs. 5.9%;
HR 0.71 (95% CI 0.59–0.85); p\0.001] and the
secondary end point of MI (2.1% vs. 4.1%; HR
0.47; p\0.001). The risk of ischemic events
increased markedly in the 3-month period after
discontinuing thienopyridine treatment,
regardless of when that occurred. However,
30 months therapy was associated with
significantly greater moderate or severe
bleeding (2.5% vs. 1.6%; p = 0.001) and higher
all-cause death [2.0% vs. 1.5%; HR 1.36 (95% CI
1.00 to 1.85); p = 0.05] mainly due to non-CV
deaths, including cancer deaths (0.62% vs.
0.28%; p = 0.02). The magnitude of benefit
appeared highest in those receiving paclitaxel-
eluting stents (27% of patients) in whom
ongoing therapy may be appropriate, whereas
shorter duration may be appropriate in new-
generation stents particularly if at increased
bleeding risk.
The Second Generation Drug-Eluting Stent
Implantation Followed by Six- Versus Twelve-
Month Dual Antiplatelet Therapy (SECURITY)
trial (ClinicalTrials.gov #NCT00944333)
randomized 1399 low-risk patients with stable
or unstable angina or documented silent
ischemia, undergoing PCI revascularization,
with a second-generation DES to either 6 or
12 months of DAPT [22]. There was no
significant difference between the two groups
in the incidence of the primary composite end
point (cardiac death, MI, stroke, definite or
probable stent thrombosis or Bleeding
Academic Research Consortium (BARC) type 3
or 5 bleeding at 12 months) occurring in 4.5%
vs. 3.7% of patients, respectively; p = 0.469).
There was also no difference in the incidence of
definite or probable stent thrombosis at
12 months (0.3% vs. 0.4%; 95% CI -0.7 to
0.4; p = 0.694). Interestingly there was no
significant excess in bleeding with longer
duration DAPT. The efficacy and safety data
were confounded by 33% of patients in the
6-month group actually continuing therapy for
12 months.
However, these and previous data have
helped to guide new ESC guidelines which
recommend 6 months of DAPT following
elective PCI with second-generation DES and
consideration of only 3 months DAPT for
patients at an increased risk of bleeding [23].
The Safety and Efficacy of 6 Months Dual
Antiplatelet Therapy After Drug Eluting
Stenting (ISAR-SAFE) study (ClinicalTrials.gov
#NCT00661206) also assessed the length of
DAPT, suggesting that 6 months may be non-
inferior [24]. It compared patients with DES PCI
who received 6 months of DAPT with aspirin
and clopidogrel, followed by 1:1 randomization
to an additional 6 months of either DAPT or
aspirin alone. This trial was terminated
prematurely due to a lower than anticipated
event rate. A total of 4005 patients were
randomized, 2007 to 12 months of DAPT and
1997 to 6 months of therapy. Baseline
characteristics were similar between the two
cohorts. The primary end point was MACE,
which was non-significantly different between
the 6- and 12-month DAPT arms. The
composite of death, MI, stroke, and stent
thrombosis was also similar (1.3% vs. 1.5%;
p = 0.59) as were individual end points of
mortality (0.4% vs. 0.6%; p = 0.37), MI (0.7%
vs. 0.7%; p = 0.85), stent thrombosis (0.3% vs.
0.2%; p = 0.74), and stroke (0.4% vs. 0.3%;
p = 0.57). Thrombolysis in myocardial
infarction (TIMI) major or minor bleeding was
numerically lower with 6 months of DAPT
(0.3% vs. 0.7%; p = 0.12) and major bleeding
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(BARC C2) was significantly reduced (1% vs.
2%; p = 0.01). Overall, ISAR-SAFE suggested that
6 months of DAPT may be non-inferior to
12 months of DAPT with a trend toward lower
bleeding. However, these results must be viewed
with caution, as the study was halted
prematurely due to a significantly lower event
rate than anticipated (actual 1.6% vs.
anticipated 10%).
The new P2Y12 antiplatelets ticagrelor and
prasugrel achieve faster onset of action and
approximately double the inhibition of platelet
aggregation. Such properties might be
expected to be of greatest benefit in acute
coronary syndromes undergoing early
intervention. In the study called A 30-day
Study to Evaluate Efficacy and Safety of Pre-
hospital vs. In-hospital Initiation of Ticagrelor
Therapy in STEMI Patients Planned for
Percutaneous Coronary Intervention
(ATLANTIC) trial (ClinicalTrials.gov
#NCT01347580) [25], 1862 patients
presenting in the community with STEMI and
planned for primary PCI were randomized to
immediate pre-hospital ticagrelor
administration versus delayed ticagrelor
administration in the cardiac catheterization
laboratory. Unexpectedly, there was no
difference in the co-primary end points of
[70% ST resolution or TIMI-3 flow between
the two groups. However, platelet function
analysis suggested that the intended early
difference in platelet inhibition at the onset
of primary PCI had not been achieved partly
due to very rapid transfer of patients (only
31 min time difference) and a probable delayed
absorption of ticagrelor in such acutely unwell
patients, particularly if morphine had been
given. A suggestion of more effective platelet
inhibition with pre-hospital ticagrelor was
noted 1 h post-PCI (p = ns), but no difference
by 6 h post-PCI. The pre-specified secondary
end point of definite stent thrombosis was less
in the pre-hospital group (0% vs. 0.8% in first
24 h; p = 0.008 and 0.2% vs. 1.2% at 30 days;
p = 0.02). Rates of major bleeding events did
not differ between the two groups. In
summary, although there was no safety
concern with pre-hospital use of ticagrelor,
since the primary end point was not reduced,
stent thrombosis observations cannot be
regarded as definitive and at present, pre-
hospital or in-hospital administration remains
reasonable.
The Treatment With Adenosine Diphosphate
(ADP) Receptor Inhibitors: Longitudinal
Assessment of Treatment Patterns and Events
After Acute Coronary Syndrome (TRANSLATE-
ACS) observational study (ClinicalTrials.gov
#NCT01088503) enrolled 11,969 ACS patients
undergoing PCI [26] who received either
clopidogrel (n = 8846) or prasugrel (n = 3123).
Unadjusted MACE rates (a composite of death,
MI, stroke, or unplanned revascularization)
were higher with clopidogrel than prasugrel
(17.3% vs. 13.5%; p\0.0001). However,
patients receiving prasugrel were more likely
to be younger, male, or presenting with STEMI
and less likely to have had a history of prior MI,
coronary artery bypass graft (CABG), or
stroke/transient ischemic attack. After
adjustment for baseline population differences,
there was no longer any difference in overall
MACE, although clopidogrel was associated
with a higher risk of stent thrombosis but a
lower risk of bleeding in keeping with previous
randomized data.
Anticoagulation
The Explore the Efficacy and Safety of Once-
Daily Oral Rivaroxaban for the Prevention of
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Cardiovascular Events in Patients With
Nonvalvular Atrial Fibrillation Scheduled for
Cardioversion (X-VeRT) trial (ClinicalTrials.gov
#NCT01674647) randomized 1504 patients
with atrial fibrillation (AF) of presumed
duration [48 h and undergoing elective
cardioversion [27] to the new oral
anticoagulant rivaroxaban (20 mg once daily,
15 mg if creatinine clearance 30–49 mL/min) or
dose-adjusted warfarin in a 2:1 ratio.
Additionally, investigators could randomize
patients to either an early (target period of
1–5 days after randomization) or delayed
(3–8 weeks) cardioversion strategy. The
primary outcome (stroke, transient ischemic
attack, peripheral embolism, MI, or CV death)
occurred in 5 (two strokes) of 978 patients
(0.51%) receiving rivaroxaban (4 with early
cardioversion and 1 with delayed
cardioversion), compared with 5 (two strokes)
of 492 patients (1.02%) receiving warfarin (3
with early cardioversion and 2 with delayed
cardioversion). Although the study was only
exploratory and not powered to provide
statistically rigorous results (which would have
required[10 9 the numbers), the findings are
reassuring and in keeping with previous post
hoc data from new oral anticoagulant trials.
Transcatheter Aortic Valve Implantation
Transcatheter aortic valve implantation (TAVI)
has become standard cardiology practice in
patients with severe aortic stenosis deemed not
suitable for conventional surgery. Although
initially greeted with skepticism, the importance
of the procedure was recently highlighted
by long-term follow-up of the Placement of
Aortic Transcatheter Valves (PARTNER) study
(ClinicalTrials.gov #NCT00530894) [28] which
reported a 47% reduction in 3-year mortality
rate for TAVI compared with standard medical
therapy (54.1% vs. 80.9%; HR 0.53; 95% CI
0.41–0.68; p\0.001).
Who should undergo TAVI has been a topic
of debate addressed by a number of large trials.
The multicenter randomized CoreValve High-
Risk Study (ClinicalTrials.gov #NCT01645202)
randomized 795 high-risk severe aortic stenosis
patients from 45 centers to TAVI or
conventional surgery [29]. TAVI was
performed using the Medtronic CoreValve
group (323 via the iliofemoral route and 67 via
non-iliofemoral access). The primary end point,
1 year all-cause mortality, was significantly
lower with TAVI (14.2% vs. 19.1%; p = 0.04).
TAVI was non-inferior with respect to
functional status and quality of life. As
expected, the TAVI group had more major
vascular complications, paravalvular leaks, and
permanent pacemaker implantation, while the
surgical group had higher rates of bleeding,
acute kidney injury, and atrial fibrillation. The
rate of stroke was not statistically different.
The Observational Study of Appropriateness,
Efficacy and Effectiveness of AVR-TAVR
Procedures for the Treatment of Severe
Symptomatic Aortic Stenosis (OBSERVANT)
observational cohort registry [30] enrolled
intermediate risk patients with severe aortic
stenosis and severe LV systolic dysfunction,
eligible for TAVI (n = 650) or surgery (n = 650).
Patients were matched for age, gender, baseline
co-morbidities, previous interventions, priority
at hospital admission, frailty score, and NYHA
class. Exclusion criteria included requirement
for concurrent revascularization, use of
transapical TAVI, porcelain aorta, or hostile
thorax. Despite the lower EuroScore surgical
risk than in previous PARTNER [28] and
CoreValve High-Risk studies [29], the 1 year
OBSERVANT mortality rates presented at TCT
[31] also showed no significant difference
between TAVI and surgical groups (13.3% vs.
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13.1%; p = 0.936), MACE, cardiac
rehospitalization, or HF admissions. The
conclusions of the authors in this study
suggest that in patients with severe LV systolic
dysfunction, TAVI (at least via the transfemoral
route) appears a reasonable alternative to
conventional surgery. However, it is important
to be cautious with regard to this, as the data
presented are not randomized and not in
keeping with the conventional view that aortic
stenosis is best treated with surgical aortic valve
replacement. The forthcoming Placement of
AoRTic TraNscathetER Valves (PARTNER II)
(ClinicalTrials.gov #NCT01314313) and Safety
and Efficacy Study of the Medtronic CoreValve
System in the Treatment of Severe,
Symptomatic Aortic Stenosis in Intermediate
Risk Subjects Who Need Aortic Valve
Replacement (SURTAVI) (ClinicalTrials.gov
#NCT01586910) studies will help further
evaluate TAVI in low- and intermediate-risk
patients [32, 33].
Stable Coronary Artery Disease
Previous subgroup analysis suggested that the
sino-atrial node-blocking agent ivabradine may
improve outcomes in patients with stable
coronary artery disease and a heart rate of 70
beats per minute or more, especially among
those with limiting angina [34]. Study Assessing
the Morbidity-Mortality Benefits of the If
Inhibitor Ivabradine in Patients with Coronary
Artery Disease (SIGNIFY) (EudraCT #2009-
011360-10) [35] randomized 19,102 patients
with stable coronary artery disease without
clinical HF, heart rate C70 beats per minute to
ivabradine or placebo. Over the 28.7 months
follow-up, there was no difference in the
primary end point of CV death or nonfatal MI
between the cohorts (6.8% and 6.4%,
respectively; HR 1.08; 95% CI 0.96–1.20;
p = 0.20). Unexpectedly, ivabradine was
associated with an increase in the primary end
point among patients with limiting angina
(12,049 patients had Canadian Cardiovascular
Society class CII angina), but not among those
without limiting angina (p interaction = 0.02).
Ivabradine, which was at doses up to 10 mg
twice a day (higher than currently licensed), was
associated with a marked increase in
bradycardia (18.0% vs. 2.3%; p\0.001). While
heart rate lowering remains of symptomatic
value for stable angina, this important and well-
conducted trial challenges the commonly held
view regarding prognostic benefit. In particular,
excessive heart rate lowering may be
disadvantageous.
The value of invasive fractional flow reserve
(FFR) assessment of moderate coronary stenoses
is gaining increasingly wide clinical acceptance.
The multicenter Portuguese Study on the
Evaluation of FFR Guided Treatment of
Coronary Disease (POST-IT) registry
(ClinicalTrials.gov #NCT01835808) [36] at
EuroPCR 2014 described how, compared with
standard quantitative coronary angiography
alone, use of FFR changed physicians’ choice of
treatment in44%of 918patients from19centers.
Specifically, while the overall number of PCI did
not change significantly, the number of elective
CABG referrals declined by almost 50%.
In the Fractional Flow Reserve (FFR) Guided
Percutaneous Coronary Intervention Plus
Optimal Medical Treatment Versus Optimal
Medical Therapy alone (FAME II) trial
(ClinicalTrials.gov #NCT01132495), stable
patients (n = 1220) scheduled for elective PCI
first underwent pressure wire assessment for FFR
[37]. Those patients (n = 888) with at least one
coronary lesion FFR B0.80 were randomized to
PCI plus medical therapy versus medical
therapy alone. Those with FFR[0.80 were not
randomized, but received medical therapy only
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and registry follow-up. Within the FFR B0.80
group, PCI plus medical therapy versus medical
therapy alone was associated with significant
reduction in the primary end point of death,
MI, or urgent revascularization (8.1% vs. 19.5%;
HR 0.39; 95% CI 0.26–0.57; p\0.001) driven by
a lower rate of urgent revascularization.
Although there were no significant differences
in the rates of death and MI overall, in a
landmark analysis the rate of death or MI from
8 days to 2 years was lower in the PCI group
than in the medical therapy group (4.6% vs.
8.0%; p = 0.04). Of note, the use of PCI reduced
event rates similar to that seen in the registry of
patients with non-obstructive disease (FFR
[0.80) in whom the primary end point was
9.0% at 2 years.
Arrhythmias and Devices
Cardiac resynchronization therapy (CRT) has
been proven to improve HF symptoms and
outcomes in patients with LV dysfunction and a
broad QRS complex on electrocardiography [38,
39].However, failure to implant anLV leadoccurs
in approximately 5–15%of cases [40, 41]. Reasons
for this include unsatisfactory pacing parameters
and phrenic nerve stimulation (PNS). The
presence of more electrodes on the LV lead may
allowachange inpacingvectorwhichmay reduce
PNSandunsatisfactorypacingcapture thresholds.
The multicenter More Options Available with a
Quadripolar LV Lead Provide In-clinic Solutions
to CRT Challenges (MORE CRT) trial
(ClinicalTrials.gov #NCT01510652) randomized
1068 patients undergoing CRT to receive
quadripolar (n = 720) or bipolar (n = 348) leads
[42]. Patients were evaluated for intraoperative
events (including PNS, lead instability, high
capture threshold leading to change in tributary
vein of coronary sinus after target-site evaluation,
use of more than one LV lead during the
procedure, requirement for active lead fixation,
or unsuccessful implantation) and postoperative
events (related to the LV lead or abandonment of
CRT). Use of quadripolar leads compared with
bipolar leads was associated with a 40.8%
reduction in the primary composite end point of
intra- and postoperative LV lead-related events
(13.2% vs. 22.3%; p = 0.0002). Although the
study was not powered to evaluate subsequent
clinical outcomes, a quadripolar lead strategy
appears promising.
Use of pacemakers without leads may
potentially reduce transvenous and
subcutaneous complications (Fig. 3) [43]. The
LEADLESS registry (ClinicalTrials.gov
#NCT02051972) enrolled 33 patients
undergoing leadless pacemaker implantation
with the primary end point being 90 days
complication rate [44]. The implant success
rate was 97% (n = 32). One patient developed
right ventricular perforation and cardiac
tamponade during the implant procedure, and
eventually died as a result of a stroke. The
overall complication-free rate was 94%. After
90 days, pacing performance was within the
accepted range. No patient required a revision
of the system (following the index procedure),
and all implants demonstrated an adequate
safety margin in nominal pacing amplitude
and sensing threshold. This proof of concept
study suggests that single-chamber leadless
cardiac pacemaker implantation appears
feasible. Larger studies are planned to further
evaluate the efficacy and safety compared with
conventional lead-based systems.
The importance of antithrombotic therapy
in incidentally detected ambulatory atrial
fibrillation (IA-AF) has been recently
highlighted [45]. Martinez et al. compared
the 3-year incidence of stroke, all-cause
mortality, MI, and major bleeding in 5555
patients with IA-AF and in 24,705 age- and
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gender-matched controls without AF. Patients
with IA-AF had mean CHA2DS2VASc score
2.5 ± 1.5. Those with IA-AF had a
significantly higher incidence of stroke (19.4
vs. 8.4/1000 person-years; p\0.001), mortality
(40.1 vs. 20.9/1000 person-years; p\0.001),
and MI (9.0 vs. 6.5/1000 person-years;
p\0.001). In the year following IA-AF
detection, the use of oral anticoagulant
(received by 51.0%) was associated with
reduced stroke [adjusted HR 0.35 (0.17–0.71)]
and death [adjusted HR 0.56 (0.36–0.85)].
Antiplatelet treatment was only associated
with a non-significant reduction of stroke
and death. Both treatments carried a small
non-significant adjusted incidence of major
bleeding. This study supports the association
of asymptomatic AF with adverse outcomes,
which may be reduced by oral anticoagulant
but not antiplatelet treatment.
An interesting, yet small study presented at
the ESC 2014 by Anguera et al. [46] involved
quinidine administration in Brugada syndrome
patients receiving regular appropriate
implantable cardioverter defibrillator shocks.
The cohort was small with only 23 patients,
with a mean age 41 ± 13 years and 19 (82%)
being male. After a mean follow-up of
47 ± 43 months using quinidine, there was a
significant reduction in the median number of
shocks from five shocks per patient
[interquartile range (IQR) 3, 5–7] to a median
of zero (IQR 0–0). Side effects were seen in four
(17%) patients who were managed with
Fig. 3 Leadless pacemaker, with slide showing its actual size. Nanostim and St. Jude Medical are trademarks of St. Jude
Medical, Inc. or its related companies. Reprinted with permission of [43]
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reduction of the doses of quinidine. Thus in
patients with Brugada syndrome and recurrent
ventricular shocks, it may be reasonable to
consider quinidine administration to try and
reduce shock frequency.
Atherosclerosis
Until now, the clinical value of the non-statin
lipid-lowering agent ezetimibe has been unclear.
It typically reduces low-density lipoprotein
cholesterol (LDL-C) by 15–20% and is usually
well tolerated, but did not reduce progression of
carotid intima media thickness in a previous
study of patients with familial hyperlipidemia.
Examining Outcomes in Subjects With Acute
Coronary Syndrome: Vytorin (Ezetimibe/
Simvastatin) vs. Simvastatin (IMPROVE-IT;
ClinicalTrials.gov #NCT00202878) [47]
randomized 18144 patients with ACS B10 days
and low LDL-C (\2.6 mmol/l if prior lipid-
lowering therapy; otherwise \3.2 mmol/l) to
simvastatin (40 or 80 mg) versus simvastatin
plus ezetimibe 10 mg aiming for LDL-C
\2.0 mmol/l. IMPROVE-IT was designed to test
twohypotheses: (1) if loweringLDL-C is better for
CV outcomes even at very low baseline LDL-C
and (2) if adding another non-statin LDL-
lowering drug to a statin reduces CV outcomes.
Interim analysis guided the increase in study size
(originally 10,000 patients) and follow-up was
extendedup to 7 years until at least 5250 subjects
experienced a primary end-point first event (CV
death,MI, re-hospitalization forunstable angina,
coronary revascularization, or stroke). At
baseline, the mean LDL-C level was 2.4 mmol/l
in both treatment arms. At 1 year, simvastatin
alone (27% uptitrated to 80 mg) lowered LDL-C
to a mean of 1.8 mmol/l, whereas simvastatin
(6% uptitrated to 80 mg) plus ezetimibe lowered
LDL-C to amean of 1.4 mmol/l. The well-treated
population (already at low LDL-C, with both
study arms receiving statin) and study
prolongation (increasing drop outs/loss to
follow-up and the impact of recurrent vascular
events) suggested itmight be difficult tomeet the
primary end point. Despite this, addition of
ezetimibe to simvastatin reduced the primary
end point by 6.4% (34.7% vs. 32.7%; p = 0.016)
(Fig. 4), driven by a significant reduction in MI
(14.8% vs. 13.1%; p = 0.002) and ischemic stroke
(4.1% vs. 3.4%; p = 0.008) (Fig. 5). Although
absolute risk reduction was not marked,
IMPROVE-IT is a key trial, being the first to
demonstrate incremental clinical benefit when
adding a non-statin agent (ezetimibe) to statin
therapy.
The Study of Alirocumab (REGN727/
SAR236553) in Patients With Primary
Hypercholesterolemia and Moderate, High, or
Very High Cardiovascular (CV) Risk, Who Are
Intolerant to Statins (ODYSSEY ALTERNATIVE;
ClinicalTrials.gov #NCT01709513) trail [48]
evaluated the PCKS9 monoclonal antibody
alirocumab patients with statin intolerance
and LDL-C[1.8 mmol/l if very high CV risk or
LDL [2.6 mmol/l if moderate/high risk. Mean
baseline LDL-C was 4.9 mmol/l. Following a
4-week placebo run-in phase (during which 47
patients dropped out because of muscle-related
symptoms), 314 patients were randomized to
subcutaneous injection with alirocumab
75–150 mg every 2 weeks (n = 126), ezetimibe
10 mg (n = 125) or atorvastatin 20 mg (n = 63).
Alirocumab lowered LDL-C levels significantly
more than ezetimibe by 24 weeks (intention to
treat -45.0% vs. -14.6%; p\0.0001 and on-
treatment -52.2% vs. -17.1%; p\0.0001).
Alirocumab was better tolerated than
atorvastatin and produced greater LDL
reductions. Given the positive results of a non-
statin drug ezetimibe in IMPROVE-IT, it is thus
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Fig. 5 IMPROVE-IT: individual cardiovascular end points
and CVD/MI/stroke. Reproduced with permission from
[47]. CHD coronary heart disease, Cor revasc coronary
artery revascularization, CVD cardiovascular disease, EZ
ezetimibe, HR hazard ratio, MI myocardial infarction,
Simva simvastatin, UA unstable angina
Fig. 4 IMPROVE-IT primary end point: cardiovascular
death, MI, documented unstable angina requiring rehospi-
talization, coronary revascularization (C30 days), or stroke.
Reproduced with permission from [47]. CI conﬁdence
interval, EZ ezetimibe, HR hazard ratio, NNT numbers
needed to treat, Simva simvastatin
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hoped that PCSK9 inhibitors will also be
associated with clinical benefit in ongoing CV
outcome trials.
The value in cardiac screening in
asymptomatic patients has long been
controversial [49]. The Screening For
Asymptomatic Obstructive Coronary Artery
Disease Among High-Risk Diabetic Patients
Using CT Angiography, Following Core 64
(FACTOR-64) trial (ClinicalTrials.gov
#NCT00488033) randomized 900 diabetic
patients to either cardiac computerized
tomography angiography (CCTA) screening
(n = 452) or to standard national guidelines-
based optimal diabetes care (n = 448). Those in
the CCTA arm could receive subsequent
invasive coronary angiography, based on
CCTA findings. After a mean follow-up of
4 years, the primary outcome (all-cause
mortality, nonfatal MI, or unstable angina
requiring hospitalization) showed a small, but
non-significant reduction with CCTA screening
[6.2% (28 events) vs. 7.6% (34 events); HR 0.80
(95% CI 0.49–1.32); p = 0.38]. At present, such
data do not support routine CCTA screening in
high-risk diabetic patients, although larger
studies with greater power are being
undertaken.
CONCLUSION
Over the past year, a number of important
advances have been presented in major
international cardiology meetings. Some
findings are ready to influence clinical
practice, while others require additional
discussion and integration, or further work,
before clinical adoption. This review has
highlighted the most important trials, thus
giving an overview of the most important
breaking research from 2014.
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